Analysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $43.17

Spyre Therapeutics, Inc. (NASDAQ:SYRE) has been assigned an average rating of “Buy” from the eight research firms that are covering the stock, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have covered the stock in the last year is $43.17.

A number of equities research analysts have recently commented on the stock. BTIG Research upped their price objective on shares of Spyre Therapeutics from $32.00 to $40.00 and gave the company a “buy” rating in a research note on Friday, May 10th. Wells Fargo & Company boosted their price objective on Spyre Therapeutics from $35.00 to $40.00 and gave the company an “overweight” rating in a research note on Monday, May 13th. Robert W. Baird assumed coverage on Spyre Therapeutics in a research note on Thursday, May 2nd. They set an “outperform” rating and a $50.00 target price for the company. Finally, Stifel Nicolaus boosted their price target on Spyre Therapeutics from $36.00 to $54.00 and gave the company a “buy” rating in a research note on Tuesday, March 26th.

Spyre Therapeutics Stock Up 0.9 %

Shares of NASDAQ:SYRE opened at $28.13 on Friday. The firm has a market cap of $1.13 billion, a P/E ratio of -0.39 and a beta of 2.94. Spyre Therapeutics has a 12-month low of $8.43 and a 12-month high of $47.97. The business has a fifty day simple moving average of $31.39 and a 200 day simple moving average of $30.49.

Spyre Therapeutics (NASDAQ:SYRE) last issued its quarterly earnings data on Monday, May 13th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). As a group, equities research analysts expect that Spyre Therapeutics will post -3.82 EPS for the current year.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).